1009818-08-9

Upstream product

• 67-56-1 methanol 
• 23202-83-7 5-benzyl-1,2-O-isopropylidene-α-D-xylofuranose 

Downstream Products

• 1009818-28-3 C₁₉H₃₂O₅Si 
• 1009818-27-2 C₁₉H₃₂O₅Si 
• 29024-87-1 methyl 5-O-benzyl-2,3-anhydro-β-D-lyxofuranoside 
• 133776-28-0 methyl 5-O-benzyl-3-fluoro-3-deoxy-β-D-ribofuranoside 
• 1101107-81-6 (3S,4S,5R)-5-((benzyloxy)methyl)-4-fluoro-2-methoxytetrahydrofuran-3-ol 
• 170871-87-1 N-(9-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 129054-67-7 N-(9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 123484-12-8 ((2R,3R,4S)-5-acetoxy-4-(benzoyloxy)-3-fluorotetrahydrofuran-2-yl)methyl benzoate 

Relevant academic research and scientific papers

HSCN condensation with ulosides: preferred formation of carbohydrate-fused hemiaminals of the 4-hydroxy-1,3-oxazolidine-2-thione type

Selected ulofuranosides and ulopyranosides react with thiocyanic acid to give good yields of stable carbohydrate-fused hemiaminal 1,3-oxazolidine-2-thiones.

NOVEL STING AGONISTS

The present invention provides compounds of Formula I′: wherein , W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.